Literature DB >> 11113152

The regulation of type 7 adenylyl cyclase by its C1b region and Escherichia coli peptidylprolyl isomerase, SlyD.

S Z Yan1, J A Beeler, Y Chen, R K Shelton, W J Tang.   

Abstract

Mammalian membrane-bound adenylyl cyclase consists of two highly conserved cytoplasmic domains (C1a and C2a) separated by a less conserved connecting region, C1b, and one of two transmembrane domains, M2. The C1a and C2a domains form a catalytic core that can be stimulated by forskolin and the stimulatory G protein subunit alpha (Galpha(s)). In this study, we analyzed the regulation of type 7 adenylyl cyclase (AC7) by C1b. The C1a, C1b, and C2a domains of AC7 were purified separately. Escherichia coli SlyD protein, a cis-trans peptidylprolyl isomerase (PPIase), copurifies with AC7 C1b (7C1b). SlyD protein can inhibit the Galpha(s)- and/or forskolin-activated activity of both soluble and membrane-bound AC7. Mutant forms of SlyD with reduced PPIase activity are less potent in the inhibition of AC7 activity. Interestingly, different isoforms of mammalian membrane-bound adenylyl cyclase can be either inhibited or stimulated by SlyD protein, raising the possibility that mammalian PPIase may regulate enzymatic activity of mammalian adenylyl cyclase. Purified 7C1b-SlyD complex has a greater inhibitory effect on AC7 activity than SlyD alone. This inhibition by 7C1b is abolished in a 7C1b mutant in which a conserved glutamic acid (amino acid residue 582) is changed to alanine. Inhibition of adenylyl cyclase activity by 7C1b is further confirmed by using 7C1b purified from an E. coli slyD-deficient strain. This inhibitory activity of AC7 is also observed with the 28-mer peptides derived from a region of C1b conserved in AC7 and AC2 but is not observed with a peptide derived from the corresponding region of AC6. This inhibitory activity exhibited by the C1b domain may result from the interaction of 7C1b with 7C1a and 7C2a and may serve to hold AC7 in the basal nonstimulated state.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11113152     DOI: 10.1074/jbc.M010361200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  14 in total

1.  Gene delivery mediated by recombinant silk proteins containing cationic and cell binding motifs.

Authors:  Keiji Numata; Juliana Hamasaki; Balajikarthick Subramanian; David L Kaplan
Journal:  J Control Release       Date:  2010-05-10       Impact factor: 9.776

2.  A Novel CRISPR/Cas9-Based Cellular Model to Explore Adenylyl Cyclase and cAMP Signaling.

Authors:  Monica Soto-Velasquez; Michael P Hayes; Aktan Alpsoy; Emily C Dykhuizen; Val J Watts
Journal:  Mol Pharmacol       Date:  2018-06-27       Impact factor: 4.436

3.  Spider silk-based gene carriers for tumor cell-specific delivery.

Authors:  Keiji Numata; Michaela R Reagan; Robert H Goldstein; Michael Rosenblatt; David L Kaplan
Journal:  Bioconjug Chem       Date:  2011-07-12       Impact factor: 4.774

4.  Cloning, overexpression, purification and preliminary characterization of human septin 8.

Authors:  T A C B Souza; J A R G Barbosa
Journal:  Protein J       Date:  2010-07       Impact factor: 2.371

5.  Isoform selectivity of adenylyl cyclase inhibitors: characterization of known and novel compounds.

Authors:  Cameron S Brand; Harrison J Hocker; Alemayehu A Gorfe; Claudio N Cavasotto; Carmen W Dessauer
Journal:  J Pharmacol Exp Ther       Date:  2013-09-04       Impact factor: 4.030

6.  Antimicrobial functionalized genetically engineered spider silk.

Authors:  Sílvia C Gomes; Isabel B Leonor; João F Mano; Rui L Reis; David L Kaplan
Journal:  Biomaterials       Date:  2011-03-31       Impact factor: 12.479

7.  Novel nanocomposites from spider silk-silica fusion (chimeric) proteins.

Authors:  Cheryl Wong Po Foo; Siddharth V Patwardhan; David J Belton; Brandon Kitchel; Daphne Anastasiades; Jia Huang; Rajesh R Naik; Carole C Perry; David L Kaplan
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-12       Impact factor: 11.205

Review 8.  International Union of Basic and Clinical Pharmacology. CI. Structures and Small Molecule Modulators of Mammalian Adenylyl Cyclases.

Authors:  Carmen W Dessauer; Val J Watts; Rennolds S Ostrom; Marco Conti; Stefan Dove; Roland Seifert
Journal:  Pharmacol Rev       Date:  2017-04       Impact factor: 25.468

9.  Bioengineered silk protein-based gene delivery systems.

Authors:  Keiji Numata; Balajikarthick Subramanian; Heather A Currie; David L Kaplan
Journal:  Biomaterials       Date:  2009-07-04       Impact factor: 12.479

10.  Bioengineered chimeric spider silk-uranium binding proteins.

Authors:  Sreevidhya Tarakkad Krishnaji; David L Kaplan
Journal:  Macromol Biosci       Date:  2012-12-04       Impact factor: 4.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.